Clinical Trial Update: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating intravesical Bacillus Calmette-Guérin in combination with ALT-803 (N-803) for non-muscle invasive bladder cancer; the trial is acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)
• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Non-muscle Invasive Bladder Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING